195 related articles for article (PubMed ID: 17665482)
1. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.
Bansback N; Marra C; Tsuchiya A; Anis A; Guh D; Hammond T; Brazier J
Arthritis Rheum; 2007 Aug; 57(6):963-71. PubMed ID: 17665482
[TBL] [Abstract][Full Text] [Related]
2. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
[TBL] [Abstract][Full Text] [Related]
3. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
[TBL] [Abstract][Full Text] [Related]
4. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
[TBL] [Abstract][Full Text] [Related]
5. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
Wolfe F; Michaud K; Wallenstein G
J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
[TBL] [Abstract][Full Text] [Related]
6. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
7. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
[TBL] [Abstract][Full Text] [Related]
8. Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis.
Amjadi SS; Maranian PM; Paulus HE; Kaplan RM; Ranganath VK; Furst DE; Khanna PP; Khanna D;
J Rheumatol; 2009 Jun; 36(6):1150-7. PubMed ID: 19369459
[TBL] [Abstract][Full Text] [Related]
9. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
10. Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain.
Carreño A; Fernández I; Badia X; Varela C; Roset M
Value Health; 2011 Jan; 14(1):192-200. PubMed ID: 21211502
[TBL] [Abstract][Full Text] [Related]
11. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
Dritsaki M; Petrou S; Williams M; Lamb SE
Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
[TBL] [Abstract][Full Text] [Related]
12. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
13. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?
Marra CA; Rashidi AA; Guh D; Kopec JA; Abrahamowicz M; Esdaile JM; Brazier JE; Fortin PR; Anis AH
Qual Life Res; 2005 Jun; 14(5):1333-44. PubMed ID: 16047508
[TBL] [Abstract][Full Text] [Related]
14. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
Lillegraven S; Kristiansen IS; Kvien TK
Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
[TBL] [Abstract][Full Text] [Related]
15. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.
Buitinga L; Braakman-Jansen LM; Taal E; Kievit W; Visser H; van Riel PL; van de Laar MA
Arthritis Care Res (Hoboken); 2012 Jun; 64(6):826-32. PubMed ID: 22262513
[TBL] [Abstract][Full Text] [Related]
16. Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.
McDonough CM; Grove MR; Elledge AD; Tosteson AN
Osteoporos Int; 2012 Feb; 23(2):723-32. PubMed ID: 21484360
[TBL] [Abstract][Full Text] [Related]
17. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
[TBL] [Abstract][Full Text] [Related]
18. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the EQ-5D and the SF-6D utility measures in 813 patients with early arthritis: results from the ESPOIR cohort.
Gaujoux-Viala C; Rat AC; Guillemin F; Flipo RM; Fardellone P; Bourgeois P; Fautrel B
J Rheumatol; 2011 Aug; 38(8):1576-84. PubMed ID: 21532054
[TBL] [Abstract][Full Text] [Related]
20. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
